132 related articles for article (PubMed ID: 14602136)
1. Cytokine-regulated expression of collagenase-2 (MMP-8) is involved in the progression of ovarian cancer.
Stadlmann S; Pollheimer J; Moser PL; Raggi A; Amberger A; Margreiter R; Offner FA; Mikuz G; Dirnhofer S; Moch H
Eur J Cancer; 2003 Nov; 39(17):2499-505. PubMed ID: 14602136
[TBL] [Abstract][Full Text] [Related]
2. Expression levels of vascular endothelial growth factor, matrix metalloproteinases 2 and 9 and tissue inhibitor of metalloproteinases 1 and 2 in the plasma of patients with ovarian carcinoma.
Manenti L; Paganoni P; Floriani I; Landoni F; Torri V; Buda A; Taraboletti G; Labianca R; Belotti D; Giavazzi R
Eur J Cancer; 2003 Sep; 39(13):1948-56. PubMed ID: 12932675
[TBL] [Abstract][Full Text] [Related]
3. Matrix metalloproteinase-9 expression correlates with prognosis and involved in ovarian cancer cell invasion.
Hu X; Li D; Zhang W; Zhou J; Tang B; Li L
Arch Gynecol Obstet; 2012 Dec; 286(6):1537-43. PubMed ID: 22832979
[TBL] [Abstract][Full Text] [Related]
4. Expression of matrix metalloproteinases (MMP-2, MMP-9, MT1-MMP) and their inhibitors (TIMP-1, TIMP-2) in common epithelial tumors of the ovary.
Sakata K; Shigemasa K; Nagai N; Ohama K
Int J Oncol; 2000 Oct; 17(4):673-81. PubMed ID: 10995877
[TBL] [Abstract][Full Text] [Related]
5. [Expression of matrix metalloproteinases-9,2,7,and tissue inhibitor of metalloproteinases-1,2,3 mRNA in ovarian tumors and their clinical significance].
Hu XX; Li L; Li DR; Zhang W; Cheng XQ; Zhang JQ; Tang BJ
Ai Zheng; 2004 Oct; 23(10):1194-8. PubMed ID: 15473934
[TBL] [Abstract][Full Text] [Related]
6. Matrix metalloproteinases and tissue inhibitors of metalloproteinases in human gliomas.
Nakano A; Tani E; Miyazaki K; Yamamoto Y; Furuyama J
J Neurosurg; 1995 Aug; 83(2):298-307. PubMed ID: 7616276
[TBL] [Abstract][Full Text] [Related]
7. Expression of matrix metalloproteinases and related tissue inhibitors in the cyst fluids of ovarian mucinous neoplasms.
Furuya M; Ishikura H; Kawarada Y; Ogawa Y; Sakuragi N; Fujimoto S; Yoshiki T
Gynecol Oncol; 2000 Aug; 78(2):106-12. PubMed ID: 10926788
[TBL] [Abstract][Full Text] [Related]
8. Profile of Metalloproteinases and Their Association with Inflammatory Markers in Pleural Effusions.
Teixeira LR; Dias MB; Sales RK; Antonangelo L; Alvarenga VA; Puka J; Marchi E; Acencio MM
Lung; 2016 Dec; 194(6):1021-1027. PubMed ID: 27677622
[TBL] [Abstract][Full Text] [Related]
9. Expression of collagenase-1 (MMP-1), collagenase-3 (MMP-13) and tissue inhibitor of matrix metalloproteinase-1 (TIMP-1) in laryngeal squamous cell carcinomas.
Krecicki T; Fraczek M; Jelen M; Podhorska M; Szkudlarek T; Zatonski T
Eur Arch Otorhinolaryngol; 2003 Oct; 260(9):494-7. PubMed ID: 12739032
[TBL] [Abstract][Full Text] [Related]
10. Modulation of matrix metalloproteinase and TIMP-1 expression by cytokines in human RPE cells.
Eichler W; Friedrichs U; Thies A; Tratz C; Wiedemann P
Invest Ophthalmol Vis Sci; 2002 Aug; 43(8):2767-73. PubMed ID: 12147614
[TBL] [Abstract][Full Text] [Related]
11. Expression of latent matrix metalloproteinase 9 (MMP-9) predicts survival in advanced ovarian cancer.
Lengyel E; Schmalfeldt B; Konik E; Späthe K; Härting K; Fenn A; Berger U; Fridman R; Schmitt M; Prechtel D; Kuhn W
Gynecol Oncol; 2001 Aug; 82(2):291-8. PubMed ID: 11531282
[TBL] [Abstract][Full Text] [Related]
12. Expression of matrix metalloproteinase-26 and tissue inhibitors of metalloproteinase-3 and -4 in normal ovary and ovarian carcinoma.
Ripley D; Tunuguntla R; Susi L; Chegini N
Int J Gynecol Cancer; 2006; 16(5):1794-800. PubMed ID: 17009974
[TBL] [Abstract][Full Text] [Related]
13. Analyses of matrix metalloproteinases and their inhibitors in cyst fluid of serous ovarian tumors.
Furuya M; Ishikura H; Ogawa Y; Kawarada Y; Shibata M; Fujimoto S; Yoshiki T
Pathobiology; 2000; 68(6):239-44. PubMed ID: 11493755
[TBL] [Abstract][Full Text] [Related]
14. In vitro modulation of MMP-2 and MMP-9 in human cervical and ovarian cancer cell lines by cytokines, inducers and inhibitors.
Roomi MW; Monterrey JC; Kalinovsky T; Rath M; Niedzwiecki A
Oncol Rep; 2010 Mar; 23(3):605-14. PubMed ID: 20126997
[TBL] [Abstract][Full Text] [Related]
15. A quantitative gene expression profile of matrix metalloproteinases (MMPS) and their inhibitors (TIMPS) in the myocardium of patients with deteriorating heart failure requiring left ventricular assist device support.
Felkin LE; Birks EJ; George R; Wong S; Khaghani A; Yacoub MH; Barton PJ
J Heart Lung Transplant; 2006 Dec; 25(12):1413-9. PubMed ID: 17178334
[TBL] [Abstract][Full Text] [Related]
16. Prognostic significance of MMP-9 and TIMP-1 serum and tissue expression in breast cancer.
Wu ZS; Wu Q; Yang JH; Wang HQ; Ding XD; Yang F; Xu XC
Int J Cancer; 2008 May; 122(9):2050-6. PubMed ID: 18172859
[TBL] [Abstract][Full Text] [Related]
17. Matrix metalloproteinases (MMP-8, MMP-9) and the tissue inhibitors of metalloproteinases (TIMP-1, TIMP-2) in patients with fungal keratitis.
Rohini G; Murugeswari P; Prajna NV; Lalitha P; Muthukkaruppan V
Cornea; 2007 Feb; 26(2):207-11. PubMed ID: 17251814
[TBL] [Abstract][Full Text] [Related]
18. Matrix metalloproteinase-9,-3 and tissue inhibitor of matrix metalloproteinase-1 in colorectal cancer: relationship to clinicopathological variables.
Işlekel H; Oktay G; Terzi C; Canda AE; Füzün M; Küpelioğlu A
Cell Biochem Funct; 2007; 25(4):433-41. PubMed ID: 16615041
[TBL] [Abstract][Full Text] [Related]
19. Gelatinases and their tissue inhibitors in ovarian tumors; TIMP-1 is a predictive as well as a prognostic factor.
Rauvala M; Puistola U; Turpeenniemi-Hujanen T
Gynecol Oncol; 2005 Dec; 99(3):656-63. PubMed ID: 16112717
[TBL] [Abstract][Full Text] [Related]
20. Serum MMP-8 and TIMP-1 predict prognosis in colorectal cancer.
Böckelman C; Beilmann-Lehtonen I; Kaprio T; Koskensalo S; Tervahartiala T; Mustonen H; Stenman UH; Sorsa T; Haglund C
BMC Cancer; 2018 Jun; 18(1):679. PubMed ID: 29929486
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
